Parabilis Medicines closed at $27.25 on Nov 2, down 3.78%, 34.7% below its highest close since Sep 11. Volume of 702.3K shares was 0.58× its 20-day average (below normal).
Split-adjusted performance: -10.0% over one month.
In the quarter ended Jun 30, 2026, revenue was $148K, with a net margin of -45239.9%.
Short interest was 9.3M shares at the Oct 15 settlement, up 12.0% from the prior report (9.1% of float, 9.5 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.1%, revenue growth +6.4%, net margin −36.2%, P/E 15.8×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| PBLSParabilis Medicines | $27.25 | −3.78% | — | — | −45239.9% | — | $3.37B | |
| VKTXViking Therapeutics | $26.83 | −1.65% | −15.5% | — | — | — | $3.42B | Compare |
| ELVNEnliven Therapeutics | $44.63 | +0.86% | +7.3% | — | — | — | $3.27B | Compare |
| IRONDisc Medicine | $78.62 | −2.75% | +16.2% | — | — | — | $3.49B | Compare |
| DYNDyne Therapeutics | $17.30 | +3.65% | −2.3% | — | — | — | $3.23B | Compare |
| AMLXAmylyx Pharmaceuticals | $28.04 | −2.84% | +70.4% | — | — | — | $3.52B | Compare |
| ACADAcadia Pharmaceuticals | $20.47 | −0.58% | −7.8% | +16.4% | 10.2% | 9.3 | $3.53B | Compare |
| ABCLAbCellera Biologics | $11.12 | −9.37% | +142.3% | −76.3% | −1368.6% | — | $3.60B | Compare |
| OGNOrganon & | $13.82 | −0.14% | +4.2% | −1.7% | 10.4% | 17.0 | $3.63B | Compare |
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
